Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tenax Therapeutics, Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed a TNX-103 parent study
Investigator confirmation that participant may derive clinical benefit from continued access to TNX-103
Requirements related to childbearing potential, contraception, and egg/sperm donation
You may not be if
Investigator or Sponsor opinion that the participant is unsuitable due to safety, inability to comply, or factors that could compromise study integrity or participant well-being
Severe hepatic impairment or cirrhosis (Child-Pugh C) or active untreated hepatitis B or C with evidence of recent infection or viral replication
Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m²
Pregnancy or breastfeeding in females
Clareo Health | Long-Term Open-Label Extension Study of Oral Levosimendan
